System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Catherine Thieblemont is an expert in Hematology at Hôpital Saint-Louis (France). As of October 2026, ScienceLeadR ranks Catherine Thieblemont in the top 1% of experts worldwide for Lymphoma and Lymphoproliferative Disorders. Catherine Thieblemont has authored 887 publications, the most recent in 2026, and is an investigator in 88 clinical trials, 24 of them ongoing. SLR score: 4,364 (community average: 125). How the SLR is computed.

LeadR Profile

Catherine Thieblemont Hôpital Saint-Louis France
4 364 ScienceLeadR Reputation 4364

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1995 - 2026
Source: PubMed

INSERM

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 887

Citations

Citations: 34 593 1st author: 90 Last author: 112 Unique author: 6

Main journals

Blood 267
Hematol Oncol 58
J Clin Oncol 54
Hemasphere 40
Br J Haematol 30

Best Journals

J Clin Oncol 28
Nat Med 8
Ann Oncol 6

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
PMID 42774885 — cells, lymphoma, b-cell, lymphoma, b-lymphocytes, transplantation		Hemasphere20260
Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era.
PMID 42669939 — cells, hematology, lymphoma, b-cell, lymphoma, therapeutics, b-lymphocytes		Br J Haematol20260
Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial.
PMID 42622258 — hematology, safety, therapeutics, epcoritamab		Blood20260
The clinical picture of ICANS after CAR-T cell therapy in critically ill patients: A retrospective clustering analysis of a multicentre multinational cohort study.
PMID 42592119 — cells, incidence, confusion, cohort studies, signs and symptoms, critical illness, cluster analysis, therapeutics, t-lymphocytes, car-t cell		Ann Intensive Care20260
Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study.
PMID 42438219 — cells, lymphoma, lymphoma, mantle-cell		Br J Haematol20260

Clinical Studies 88

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3 Study Chair: 3

By phase:

Phase 3 34
Phase 2 29
Phase 1/Phase 2 11
N/A 10
Phase 1 3
Phase 2/Phase 3 1

By status:

Completed 39
Active not recruiting 22
Recruiting 16
Terminated 6
Unknown 4
Not yet recruiting 1

By type:

Interventional 79
Observational 9

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 1
multicentric5to9 5
multicentricup10 73

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

24 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma
2024-511304-16-00 — lymphoma, follicular, safety, lymphoma, rituximab		Phase 2Active not recruiting2024
OASIS II A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma
2024-512634-15-00 — cells, lymphoma, lymphoma, mantle-cell		Phase 1/Phase 2Active not recruiting2022
An unblinded multi center study evaluating long term treatment with Zanubrutinib (BGB 3111) regimens in patients with blood cancer in the lymph node
2024-511267-28-00 — cells, blood, lymph nodes, neoplasms, multiple chronic conditions, lymph, therapeutics, b-lymphocytes		Phase 3Active not recruiting2021
A Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca R) vs Investigator s Choice in Participants with Relapsed Refractory Follicular Lymphoma who have Received at least 1 Prior Line of Systemic Therapy
2024-519152-82-00 — lymphoma, follicular, safety, lymphoma, rituximab, therapeutics		Phase 3Recruiting2025
CAR T cell treatment for untreated high risk MANtle Cell Lymphoma
2022-502405-15-01 — cells, lymphoma, maintenance, rituximab, lymphoma, mantle-cell, therapeutics, t-lymphocytes, car-t cell		Phase 2Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS